Orforglipron

most data

Also seen as: Oral GLP-1 Sema, LY3502970, orfo, Oral GLP-1

The Dose Guy’s verdict

Sep 1, 2026
3 sources

Orforglipron is the first GLP-1 agonist that works as a daily pill without being a peptide, which means no injections, no cold chain, no reconstitution. It is approved and the phase 3 data is real. The honest catch: 11.2% weight loss at 72 weeks is good, but tirzepatide and retatrutide do roughly double that with a pen. The pill is the headline, not the ceiling. If you cannot or will not inject, orforglipron is your best option. If you can, the pens still win on raw effect.

Would I take it?Caution, a real GLP-1 you swallow.

What it is

A non-peptide small molecule that activates the same GLP-1 receptor the injectable drugs hit, except it survives the gut intact. Traditional GLP-1 agonists like semaglutide are peptides, which means the stomach digests them, which is why they need a needle or the special fasting-and-water trick that oral semaglutide uses. Orforglipron sidesteps the problem entirely by not being a peptide. You swallow it on an empty stomach, it absorbs intact, and it does the GLP-1 job: slows gastric emptying, kills food noise, lowers blood sugar. Daily dosing instead of weekly, because orforglipron clears faster than the injectables.

The positioning is access, not supremacy. A pill with no cold chain that a general practitioner can prescribe and a patient can start without learning to pin is a different product from tirzepatide or retatrutide on the injectable shelf, even if those pens cut deeper. The market that never started an injectable GLP-1 because of the needle or the pharmacy hassle is orforglipron’s real audience.

What the research shows

Deep phase 3 program, now approved in the US. The weight-loss numbers are solid on their own but trail the injectable leaders by a margin:

At 72 weeks, mean body-weight change was -7.5% on 6 mg, -8.4% on 12 mg, and -11.2% on 36 mg, versus -2.1% on placebo. On 36 mg, 54.6% lost at least 10% and 18.4% lost at least 20%.NEJM 2025 · ATTAIN-1 phase 3 · n=3127

After switching from injectable tirzepatide or semaglutide to oral orforglipron, patients maintained 74.7% and 79.3% of their prior weight loss at 52 weeks, versus 49.2% and 37.6% on placebo. The bridge from pen to pill works.Nat Med 2026 · ATTAIN-MAINTAIN · n=376

Pairwise meta-analysis found orforglipron increased heart rate by 7.30 bpm versus placebo. The 36 mg dose reached 9.29 bpm.Eur J Med Res 2026 · heart rate meta-analysis

Realistic protocols

Take it once daily. Food reduces absorption modestly, but the phase 3 program dosed without food or water restrictions, which is the whole point of a non-peptide oral GLP-1. The titration follows GLP-1 logic: start low, let the gut adapt, and step up only as tolerated.

The approved ramp starts at 3 mg daily and steps up in four-week increments through 6 mg and 12 mg. Most people settle at 12 mg. The top dose is 36 mg, which buys a couple more percentage points of weight loss but pushes both the GI complaints and the heart rate signal higher. Same rule as the injectable GLP-1s: if 12 mg has your hunger quiet and the scale moving, stay there.

Alcohol sits badly on any GLP-1. Slowed gastric emptying makes drinks hit harder, nausea gets worse, and most people find they simply stop wanting to drink. Worth knowing before a night out.

Start3 mg/dayThe gut-adaptation dose. Give it at least four weeks.

Raise6 mg/dayStep up if tolerated. Another four weeks before moving again.

Hold12 mg/dayWhere most people land. If hunger is managed and the scale moves, stay here.

Ceiling36 mg/dayMore weight loss, more GI, more heart rate. Push only if 12 mg stalls.

Side effects

The GLP-1 side profile, delivered daily instead of weekly:

commonNausea, vomiting, diarrhea, constipation. Clustered around dose increases, mostly mild to moderate, and the leading cause of dropout in trials.

monitorHeart rate. Roughly 7 bpm versus placebo at mid doses, up to 9 bpm at 36 mg, larger than oral semaglutide in the head-to-head trial. Check yours and take it seriously if it climbs.

monitorAppetite suppression strong enough to undershoot on protein and calories. Protect lean mass: keep protein high, keep training.

commonReduced alcohol tolerance. Drinking on any GLP-1 is a rough ride. This one is no exception.